Phase I trial of pentamethylmelamine.
Pentamethylmelamine, an analog of hexamethylmelamine developed for iv use, was administered to 42 patients in a phase I clinical trial. The dose ranged from 0.080 to 2.50 g/m2/day x 5 and was repeated approximately every 3 weeks. The dose-limiting toxic effects included moderate to severe nausea, vomiting, and central nervous system (CNS) toxicity. Myelosuppression was mild and was not dose-limiting. Antineoplastic activity was observed in four patients. Due to unacceptable gastrointestinal and CNS toxic effects from pentamethylmelamine at the active dose levels, we do not recommend disease-specific phase II trials.
D006585:Altretamine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D004341:Drug Evaluation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D014227:Triazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014227:Triazines; D006585:Altretamine; C022048:pentamethylmelamine